OBI.L (OBI.L) News
Track canonical SquawkNews coverage tagged to OBI.L, OBI.L. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Ondine Biomedical (OBI.L) reports H1 2026 operating loss of $15.90 mln
Ondine Biomedical said its H1 2026 operating loss increased to $15.90 million. It also announced the commencement of an equity fund raising process.
EARNINGS | Sep 30, 2026, 07:50 AM UTC
H
Ondine Biomedical Revises Results Timeline for US Phase 3 Study of Nasal Photodisinfection Technology
() -- Ondine Biomedical (OBI.L) said Monday it revised the timeline for results of its Lantern phase 3 study in the US evaluating its antibiotic nasal photodisinfection technology. The results are now expected within six
EARNINGS | Jul 13, 2026, 09:00 AM UTC